Archives
4 Part IgAN Experience
About This Event
4 Part IgAN Experience
An innovative, four-part educational experience designed to immerse healthcare professionals in the evolving landscape of IgA Nephropathy (IgAN) through interactive technology, evidence-based literature, real-world case studies, and high-impact educational tools.
Program Overview
Participants will engage in a dynamic dinner event that blends interactive learning with case-based discussions. The program is modular, allowing requesters to select their preferred literature topic and patient case focus, while the other elements remain consistent and highly engaging.B-Cell Biology and the Role of Cytokines in B-Cell Modulation
The physiological function of APRIL in B-cell regulation, and the growing body of evidence supporting APRIL inhibition as a potential therapeutic approach.Literature Review (Journal Club Style)
- RaDaR Study: Long-term outcomes in IgAN and the predictive value of proteinuria and eGFR decline
Apple Vision Pro Immersive Experience
Experience disease-state education like never before. Using Apple Vision Pro technology, participants can visually explore:- The 4-hit pathogenic process of IgAN
- The role of APRIL in initiating and sustaining kidney injury in IgAN
NephU Resource Station
Hands-on review of pre-approved NephU materials tailored to IgAN, including:
- Interactive simulators
- Infographics
- Educational tools and treatment summaries
Patient Case Study Review
Dive into a real-world case panel discussion on : Persistent Proteinuria in patients previously considered low riskUCLA Meyer & Renee Luskin Conference Center
Los Angeles, California 90095 United States + Google Map
Featuring
Marla Dallal, PharmD, RPH
Marla Dallal, PharmD, RPH is a Medical Science Liaison at Otsuka Pharmaceutical Development and Commercialization covering Southern California. She earned her Doctor of Pharmacy degree from the University of Southern California, School of Pharmacy in Los Angeles. While in pharmacy school, Dr Dallal pursued various clinical internships within the acute care and ambulatory care settings at Cedars-Sinai Medical Center and Kaiser Permanente. Prior to joining Otsuka, Dr Dallal held various positions within Medical Affairs at Amgen Inc covering the cardiometabolic and nephrology therapeutic areas. She also served as a preceptor at Amgen Inc, where she instructed pharmacy students on Advanced Pharmacy Practice rotations. She is currently licensed as a pharmacist in the state of California with the National Association Board of Pharmacy.
Addis Alemayehu, PharmD
Lama Abdelnour
and Internal Medicine, she completed her internal medicine training at the University of Nevada School of Medicine in Las Vegas and her nephrology fellowship at the Keck School of Medicine of USC.
Dr. Abdelnour specializes in general nephrology, with a particular focus on glomerular diseases, including IgA nephropathy, Focal Segmental Glomerulosclerosis (FSGS), membranous nephropathy, minimal change disease, Lupus Nephritis, and ANCA vasculitis. She is also dedicated to optimizing the health and evaluation of living kidney donors.
Beyond her clinical practice, Dr. Abdelnour is a principal investigator on multiple research projects, contributing to advancements in glomerular diseases and living kidney donation.
Mohammad Kamgar
Marla Dallal, PharmD, RPH and Addis Alemayehu, PharmD are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
